Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
1.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.3K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.2K
4.2K
The Tumor Microenvironment02:17

The Tumor Microenvironment

8.1K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.1K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

9.1K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of eHsp90 in Extracellular Matrix Remodeling, Tumor Invasiveness, and Metastasis.

Cancers·2024
Same author

Extracellular Hsp90 Binds to and Aligns Collagen-1 to Enhance Breast Cancer Cell Invasiveness.

Cancers·2023
Same author

Hepatocyte Stress Increases Expression of Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif in Hepatocytes to Promote Parenchymal Inflammation and Fibrosis.

Hepatology (Baltimore, Md.)·2019
Same author

An Impermeant Ganetespib Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration that Involves Lysyl Oxidase 2-like Protein.

Cancers·2014
Same author

Pregnancy-associated breast cancers are driven by differences in adipose stromal cells present during lactation.

Breast cancer research : BCR·2014
Same author

Extracellular heat shock protein (Hsp)70 and Hsp90α assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion.

PloS one·2011
Same journal

Cancer immunotherapy with oncolytic myxoma virus.

Advances in cancer research·2026
Same journal

Cancer terminator viruses: Unique conditionally replication competent oncolytic viruses producing therapeutic anti-cancer immunomodulating agents.

Advances in cancer research·2026
Same journal

Advancing clinical translation of oncolytic adenoviruses.

Advances in cancer research·2026
Same journal

Operation oncolysis: Reoviruses in the theater of cancer war.

Advances in cancer research·2026
Same journal

AAV vectors for cancer gene therapy.

Advances in cancer research·2026
Same journal

Vesicular stomatitis virus (VSV) as an oncolytic therapeutic agent for cancer.

Advances in cancer research·2026
See all related articles

Related Experiment Video

Updated: Mar 25, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

15.3K

Emerging Roles of Extracellular Hsp90 in Cancer.

Daniel Senh Wong1, Daniel G Jay2

  • 1Graduate Program in Cellular and Molecular Physiology, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts, USA.

Advances in Cancer Research
|February 27, 2016
PubMed
Summary
This summary is machine-generated.

Heat shock protein 90 (Hsp90) has a new role outside cancer cells. Extracellular Hsp90 (eHsp90) is key in tumor invasiveness and metastasis, offering a potential new drug target with reduced toxicity.

Keywords:
CancerExosomesExtracellular Hsp90InvasionMetastasisSignaling

More Related Videos

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

7.2K
Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology
09:39

Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology

Published on: March 31, 2022

3.8K

Related Experiment Videos

Last Updated: Mar 25, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

15.3K
Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

7.2K
Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology
09:39

Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology

Published on: March 31, 2022

3.8K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Heat shock protein 90 (Hsp90) is a crucial chaperone protein involved in numerous cellular processes.
  • Hsp90 is a significant target in cancer therapy, with many clinical trials investigating Hsp90 inhibitors.
  • Recent findings reveal a novel role for extracellular Hsp90 (eHsp90) beyond its intracellular functions.

Purpose of the Study:

  • To review the current understanding of extracellular Hsp90 (eHsp90) in cancer.
  • To discuss the implications of eHsp90 in tumor invasiveness and metastasis.
  • To explore the potential of eHsp90 as a biomarker and therapeutic target.

Main Methods:

  • Literature review of studies investigating Hsp90 and eHsp90.
  • Analysis of research on the role of eHsp90 in cancer cell surface and microenvironment.
  • Evaluation of the potential for targeted therapies against eHsp90.

Main Results:

  • Extracellular Hsp90 (eHsp90) plays a critical role in regulating tumor invasiveness and metastasis.
  • eHsp90 is preferentially detected on the surface of tumor cells and in the tumor microenvironment.
  • Targeting eHsp90 may offer a strategy for cancer treatment with potentially reduced toxicity.

Conclusions:

  • Extracellular Hsp90 (eHsp90) represents a significant factor in cancer progression and lethality.
  • The differential expression of eHsp90 suggests its utility as a biomarker for invasive cancers.
  • eHsp90 presents a promising and selective therapeutic target for novel cancer treatments.